jens juul holst glp-1 Dr. Holst: in Modern Medicine | Ep. 03 - The GLP-1 Podcast Show Tang Prize in Biopharmaceutical Science
Description
In my lifetime, I have not seen anything revolutionize diabetes (and certainly obesity) care in the way GLP-1 receptor agonists have in the last few years
They just become the new baseline
This combination of GLP-1 and GIP receptor activation makes Zepbound a dual receptor agonist
doi: 10.1016/j.physbeh.2010.10.017
Cognition in mood disorders
The mechanism is plausible (reward-pathway modulation) but unproven
